학술논문
Ruxolitinib in addition to standard of care for the treatment of patients admitted to hospital with COVID-19 (RUXCOVID): a randomised, double-blind, placebo-controlled, phase 3 trial
Document Type
Article
Author
Source
In: The Lancet Rheumatology . (The Lancet Rheumatology, May 2022, 4(5):e351-e361)
Subject
Language
English
ISSN
26659913